Related Experiment Video

Updated: Nov 27, 2025

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.8K

NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021

Margaret von Mehren1, John M Kane2, Marilyn M Bui3

  • 11Fox Chase Cancer Center.

Journal of the National Comprehensive Cancer Network : JNCCN
|December 7, 2020
PubMed

Insights

The NCCN updated its Soft Tissue Sarcoma guidelines, introducing distinct protocols for gastrointestinal stromal tumors and desmoid tumors. Updates also cover diagnosis, treatment, and radiation therapy for various sarcoma types.

Area of Science:

  • Oncology
  • Clinical Practice Guidelines
  • Cancer Research

Background:

  • Soft tissue sarcomas are rare cancers requiring specialized management.
  • The National Comprehensive Cancer Network (NCCN) provides evidence-based guidelines for cancer care.
  • Regular updates are essential to incorporate advancements in diagnosis and treatment.

Purpose of the Study:

  • To summarize key updates to the NCCN Guidelines for Soft Tissue Sarcoma.
  • To highlight revisions in diagnosis, treatment, and follow-up strategies.
  • To inform clinicians about recent changes in managing specific sarcoma subtypes.

Main Methods:

  • Review of NCCN panel discussions and recent guideline revisions.
  • Analysis of modifications to diagnostic and therapeutic recommendations.
  • Inclusion of new data on systemic and radiation therapy.

Main Results:

  • Establishment of a separate guideline for gastrointestinal stromal tumors (GISTs).
  • Reconceptualized management strategies for desmoid tumors.
  • Expanded recommendations for extremity/body wall, head/neck, and retroperitoneal sarcomas.
  • Updated systemic therapy regimens and radiation therapy principles for various sarcoma subtypes.

Conclusions:

  • The updated NCCN guidelines offer refined, evidence-based recommendations for soft tissue sarcoma care.
  • Specific attention has been given to GISTs, desmoid tumors, and challenging anatomical locations.
  • These revisions aim to improve patient outcomes through optimized diagnosis and treatment approaches.

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.9K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.9K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.2K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.8K